| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 82891 |
NHS ester-PEG4-VC-PAB-Daunorubicin，ADC定制 |
148 |
wyh |
2024-12-19 |
| 82892 |
Mal-PEG3-Val-Cit-PAB-OH（CAS: 2727965-49-1） |
148 |
WYQ |
2024-12-19 |
| 82893 |
cas:1539292-60-8，tert-butyl 3-(4-(2-cyanoethynyl)phenylcarbamoyl)propylcarbamate |
105 |
zyl |
2024-12-19 |
| 82894 |
1281816-04-3，Lys-Nε-MCC-DM1，ADC定制 |
106 |
wyh |
2024-12-19 |
| 82895 |
cas:34450-18-5，Alkynyl Stearic Acid，17-十八炔酸 |
179 |
zyl |
2024-12-19 |
| 82896 |
Mal-PEG4-Val-Cit-PAB-OH（CAS: 2055041-39-7） |
153 |
WYQ |
2024-12-19 |
| 82897 |
1281816-04-3，Lys-Nε-MCC-DM1，ADC定制 |
115 |
wyh |
2024-12-19 |
| 82898 |
cas:120550-35-8，Biotin-PFP ester，五氟苯酚生物素酯 |
291 |
zyl |
2024-12-19 |
| 82899 |
MTS-ADO3A 三酸DOTA衍生物 |
158 |
h |
2024-12-19 |
| 82900 |
NHS-PEG2-NH-Xanomeline，ADC定制 |
127 |
wyh |
2024-12-19 |
| 82901 |
DOTA-DAsp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH2 DOTA-CCK |
176 |
h |
2024-12-19 |
| 82902 |
DOTA-MN2 2,2’-[4,10-双(2-{[2-(2-甲基-5-硝基-1H-咪唑-1-基)乙基]氨基}-2-氧乙基)-1,4,7,10-四氮杂环十二烷-1,7-二基]二乙酸 |
121 |
h |
2024-12-19 |
| 82903 |
cas:2123482-78-8，TETRAZINE-SS-BIOTIN 四嗪-双硫键-生物素 |
118 |
zyl |
2024-12-19 |
| 82904 |
GG-Tesirine，ADC定制 |
182 |
wyh |
2024-12-19 |
| 82905 |
DOTA-PEG-A20FMDV2 DOTA偶联聚乙二醇化的20个残基的线性肽 |
203 |
h |
2024-12-19 |
| 82906 |
MC-GGFG-Exatecan，ADC定制 |
213 |
wyh |
2024-12-19 |
| 82907 |
亲和素-AMF-DOTA(Nd) |
159 |
h |
2024-12-19 |
| 82908 |
DOTA偶联人血清白蛋白微球 DOTA-HSAM |
273 |
h |
2024-12-19 |
| 82909 |
MC-VA-PBD，MC-Val-Ala-PBD，ADC定制 |
310 |
wyh |
2024-12-19 |
| 82910 |
cas:2241685-22-1，DADPS Biotin Alykne |
141 |
zyl |
2024-12-19 |
| 82911 |
MC-vc-PAB-C6-Alpha-Amanitin，ADC定制 |
138 |
wyh |
2024-12-19 |
| 82912 |
MPB-MMAF，ADC定制 |
197 |
wyh |
2024-12-19 |
| 82913 |
DOTA–Bipy–RuII配位共轭物 |
282 |
h |
2024-12-19 |
| 82914 |
cas:1007215-91-9，1-(4-formylphenyl)-1-oxo-5,8,11-trioxa-2-azatridecan-13-oic acid |
164 |
zyl |
2024-12-19 |
| 82915 |
DOTA-cT84.66 DOTA偶联单克隆抗体cT84.66 |
135 |
h |
2024-12-19 |
| 82916 |
DOTA-Ahx-(D-Lys(6)-GnRH1)金属螯合剂DOTA偶联氨基己酸缀合D-赖氨酸 |
148 |
h |
2024-12-19 |
| 82917 |
DOTA-LRB 2-(6-(二乙基氨基)-3-(二乙基亚胺基)-3H-呫吨-9-基)-5-(N-(2-(2-(4,7,10-三(羧甲基)-1,4,7,10-四氮杂环十二烷-1-基)乙酰胺基 |
152 |
h |
2024-12-19 |
| 82918 |
DOTA-Y3-TATE DOTA偶联激动剂Y3-TATE |
162 |
h |
2024-12-19 |
| 82919 |
DOTA-2-脱氧-D-氨基葡萄糖 DOTA-DG |
180 |
h |
2024-12-19 |
| 82920 |
DOTA-c(RGDfK)DOTA偶联环肽 |
121 |
h |
2024-12-19 |
| 82921 |
SCN-DOTA-PCA DOTA-苯甲酰胺衍生物 |
160 |
h |
2024-12-19 |
| 82922 |
DOTA-N-羟基琥珀酰亚胺 DOTA-N-hydroxysuccinimide |
144 |
h |
2024-12-19 |
| 82923 |
低分子量CLT1肽靶向Gd(III)螯合物CLT1-dL-(Gd-DOTA) |
228 |
h |
2024-12-19 |
| 82924 |
DOTA-1,2-二硬脂酰-sn-甘油-3-磷酸乙醇胺脂质 |
202 |
h |
2024-12-19 |
| 82925 |
1,4,7-三氮杂环壬烷-1,4,7-三乙酸(NOTA17,19) |
148 |
h |
2024-12-19 |
| 82926 |
cas:1061569-06-9，4-formyl-N-(2-(2-hydroxyethoxy)ethyl)benzamide ADC抗体偶联药物 |
118 |
zyl |
2024-12-19 |
| 82927 |
DBCO-PEG4-VA-PBD，2241644-09-5，ADC定制 |
104 |
wyh |
2024-12-19 |
| 82928 |
Val-Cit-PAB-MMAE，cas:644981-35-1，ADC定制 |
134 |
wyh |
2024-12-19 |
| 82929 |
DOTA-GMSH 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)偶联α-黑素细胞刺激素(α-MSH)类似物 |
176 |
h |
2024-12-19 |
| 82930 |
mDPR-Val-Cit-PAB-MMAE，1491152-26-1，ADC定制 |
120 |
wyh |
2024-12-19 |
| 82931 |
G3-(Gd-DTPA)(24)DOTA-钆(Gd)大分子造影剂 |
311 |
h |
2024-12-19 |
| 82932 |
DOTA-多柔比星 DOTA-DOX |
161 |
h |
2024-12-19 |
| 82933 |
聚(HPMA)-c(RGDyK)-DOTA |
108 |
h |
2024-12-19 |
| 82934 |
1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)螯合剂共轭的应变环辛烯衍生物二苄基环辛烯(DBCO) |
140 |
h |
2024-12-19 |
| 82935 |
PDDEC-NB；2-methyl-2-(pyridin-2-yldisulfanyl)propyl 4-nitrophenyl carbonate |
106 |
zyl |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询